Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still on...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/13/2/159 |
| _version_ | 1797622035608764416 |
|---|---|
| author | Masoumeh Najafi Amin Jahanbakhshi Sebastiano Finocchi Ghersi Lucia Giaccherini Andrea Botti Francesco Cavallieri Jessica Rossi Federico Iori Cinzia Iotti Patrizia Ciammella Mohsen Nabiuni Marzieh Gomar Omid Rezaie Salvatore Cozzi |
| author_facet | Masoumeh Najafi Amin Jahanbakhshi Sebastiano Finocchi Ghersi Lucia Giaccherini Andrea Botti Francesco Cavallieri Jessica Rossi Federico Iori Cinzia Iotti Patrizia Ciammella Mohsen Nabiuni Marzieh Gomar Omid Rezaie Salvatore Cozzi |
| author_sort | Masoumeh Najafi |
| collection | DOAJ |
| description | The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still one of the most aggressive and difficult to treat. So, it is critical to find more potent therapies that can help glioblastoma patients have better clinical outcomes. Additionally, the prognosis for recurring malignant gliomas is poor, necessitating the need for innovative therapeutics. Immunotherapy is a rather new treatment for glioblastoma and its effects are not well studied when it is combined with standard chemoradiation therapy. We conducted this study to evaluate different glioblastoma immunotherapy approaches in terms of feasibility, efficacy, and safety. We conducted a computer-assisted literature search of electronic databases for essays that are unique, involve either prospective or retrospective research, and are entirely written and published in English. We examined both observational data and randomized clinical trials. Eighteen studies met the criteria for inclusion. In conclusion, combining immunotherapy with radiochemotherapy and tumor removal is generally possible and safe, and rather effective in the prolongation of survival measures. |
| first_indexed | 2024-03-11T09:04:36Z |
| format | Article |
| id | doaj.art-005106bb100c47ab91378b6d2f11bc5b |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-11T09:04:36Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-005106bb100c47ab91378b6d2f11bc5b2023-11-16T19:27:00ZengMDPI AGBrain Sciences2076-34252023-01-0113215910.3390/brainsci13020159Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic ReviewMasoumeh Najafi0Amin Jahanbakhshi1Sebastiano Finocchi Ghersi2Lucia Giaccherini3Andrea Botti4Francesco Cavallieri5Jessica Rossi6Federico Iori7Cinzia Iotti8Patrizia Ciammella9Mohsen Nabiuni10Marzieh Gomar11Omid Rezaie12Salvatore Cozzi13Skull Base Research Center, Iran University of Medical Sciences, Tehran 1997667665, IranStem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran 1997667665, IranRadiation Oncolgy Unit, AOU Sant’Andrea, Facoltà di Medicina e Psicologia, Università La Sapienza, 00185 Rome, ItalyRadiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyMedical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyNeurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyNeurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyRadiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyRadiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyRadiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyDepartment of Neurosurgery, Iran Univesity of Medical Sciences, Tehran 1997667665, IranRadiation Oncology Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran 1416753955, IranHematology-Oncology Department, Jam Hospital, Tehran 1997667665, IranRadiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, ItalyThe most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still one of the most aggressive and difficult to treat. So, it is critical to find more potent therapies that can help glioblastoma patients have better clinical outcomes. Additionally, the prognosis for recurring malignant gliomas is poor, necessitating the need for innovative therapeutics. Immunotherapy is a rather new treatment for glioblastoma and its effects are not well studied when it is combined with standard chemoradiation therapy. We conducted this study to evaluate different glioblastoma immunotherapy approaches in terms of feasibility, efficacy, and safety. We conducted a computer-assisted literature search of electronic databases for essays that are unique, involve either prospective or retrospective research, and are entirely written and published in English. We examined both observational data and randomized clinical trials. Eighteen studies met the criteria for inclusion. In conclusion, combining immunotherapy with radiochemotherapy and tumor removal is generally possible and safe, and rather effective in the prolongation of survival measures.https://www.mdpi.com/2076-3425/13/2/159immunotherapychemotherapyradiotherapyglioblastomaGBMtemozolomide |
| spellingShingle | Masoumeh Najafi Amin Jahanbakhshi Sebastiano Finocchi Ghersi Lucia Giaccherini Andrea Botti Francesco Cavallieri Jessica Rossi Federico Iori Cinzia Iotti Patrizia Ciammella Mohsen Nabiuni Marzieh Gomar Omid Rezaie Salvatore Cozzi Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review Brain Sciences immunotherapy chemotherapy radiotherapy glioblastoma GBM temozolomide |
| title | Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review |
| title_full | Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review |
| title_fullStr | Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review |
| title_full_unstemmed | Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review |
| title_short | Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review |
| title_sort | clinical effects of immuno oncology therapy on glioblastoma patients a systematic review |
| topic | immunotherapy chemotherapy radiotherapy glioblastoma GBM temozolomide |
| url | https://www.mdpi.com/2076-3425/13/2/159 |
| work_keys_str_mv | AT masoumehnajafi clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT aminjahanbakhshi clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT sebastianofinocchighersi clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT luciagiaccherini clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT andreabotti clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT francescocavallieri clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT jessicarossi clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT federicoiori clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT cinziaiotti clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT patriziaciammella clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT mohsennabiuni clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT marziehgomar clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT omidrezaie clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview AT salvatorecozzi clinicaleffectsofimmunooncologytherapyonglioblastomapatientsasystematicreview |